Continuous Ketone Monitoring (CKM) for Patients with Diabetes: What Practitioners Need to Know About This New Technology
An Enduring CME Activity – 1.0 CEUs | 1 Hour Session
Diabetic ketoacidosis (DKA) is a leading cause of hospitalization for people with diabetes, accounting for hundreds of thousands of emergency room visits and hospitalizations in the U.S. each year. As clinicians on the front lines of diabetes care, we share the goal of protecting our patients from the serious threat of DKA. The arrival of Continuous Ketone Monitoring (CKM) provides a new tool to help us achieve this. By enabling earlier detection in order to institute mitigation strategies early, CKM can help reduce ER visits, hospitalizations and, most importantly, prevent deaths from DKA. Our CME activity was developed for endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, and other healthcare providers who help patients to manage type 1 and type 2 diabetes. Designed by Dr. Edelman and Dr. Pettus, both endocrinologists living with diabetes, this program aims to equip you with the information you will need regarding the application and education of CKM so that your patients and their caregivers can use this technology successfully and effectively.
Please see the full accreditation information HERE.
*To receive credit you must complete/pass the post-test and submit a program evaluation. Your certificate will auto-generate for download.*
in-depth program topics
The DKA Crisis in Diabetes: Understanding Risks and the Need for Better Monitoring Explore the high prevalence and severe risks of Diabetic Ketoacidosis (DKA), particularly in Type 1 Diabetes (T1D). This topic covers DKA pathophysiology, common risk factors, and symptoms. We’ll critically examine limitations of current urine and blood ketone (BHB) testing, establishing the urgent clinical need for advanced real-time solutions like Continuous Ketone Monitoring (CKM) to enhance patient safety in diabetes care.
Continuous Ketone Monitoring (CKM): Technology Fundamentals and Clinical Advantages Understand Continuous Ketone Monitoring (CKM) as a key advancement in diabetes technology. Learn how CKM continuously measures Beta-Hydroxybutyrate (BHB) levels, providing real-time ketone data and actionable alerts. This session highlights CKM’s benefits over traditional methods, including earlier ketosis detection, proactive DKA prevention, and an overview of the emerging CKM device landscape.
Actionable CKM Data: Interpretation for DKA Prevention and Treatment Protocols Master the practical application of CKM for improved clinical decision-making. This crucial module provides a systematic guide to interpreting continuous ketone data, understanding BHB level thresholds, and responding effectively to CKM alerts. Learn evidence-based DKA prevention strategies and treatment algorithms for CKM users, including insulin adjustments and sick day management to prevent DKA.
CKM Integration: Enhancing Clinical Workflow and Patient Empowerment Discover strategies to seamlessly integrate Continuous Ketone Monitoring (CKM) into your clinical workflow, including managing CKM patient data, urgent ketone alerts, and leveraging CKM for remote patient monitoring. Emphasis is placed on effective patient education: teaching individuals to use their CKM device, interpret ketone data, and respond to alerts for improved diabetes self-management.
Future of CKM: Driving Adoption, Innovation, and Improved Diabetes Outcomes Examine the evolving landscape and future of Continuous Ketone Monitoring (CKM) technology, including its potential integration with Automated Insulin Delivery (AID) systems. Discuss strategies to accelerate CKM acceptance, drawing lessons from CGM adoption, and address barriers like clinician training to ensure successful CKM implementation for superior DKA prevention and diabetes management.

PROGRAM OVERVIEW
- Overview and introduction to Continuous Ketone Monitoring (CKM)
- How to educate patients about DKA
- Benefits of CKM devices to prevent or reverse DKA

LEARNING OBJECTIVES
- Understand the high prevalence and risks of Diabetic Ketoacidosis (DKA)
- Be able to identify risk factors and symptoms of DKA
- Examine current DKA detection methods and their limitations
- Review CKM devices and their advantages
- Discuss how to educate patients and incorporate CKM into clinical practice

WHO CAN BENEFIT MOST
This course is designed for diabetes healthcare providers including endocrinologists, primary care physicians, nurse practitioners, physician assistants, nurses, certified diabetes educators, pharmacists, and other healthcare providers wanting to expand their knowledge of diabetes management using CKM technology.
SPEAKERS & FACULTY
*extra-relatable faculty (they're living with type 1)

Dr. Edelman is a professor of medicine in the Division of Endocrinology, Diabetes & Metabolism at the University of California, San Diego (UCSD) and the Veterans Affairs (VA) Healthcare System of San Diego. Dr. Edelman, who has type 1 diabetes himself, has written more than 200 articles, five books, and has won numerous awards for teaching and humanitarianism. He has been chosen by the medical students at UCSD as the ‘teacher of the year’ numerous times. Among his many honors, Dr. Edelman has received the ‘Diabetes Educator Of The Year’ award by the American Diabetes Association, the ‘Distinction in Endocrinology’ award by the American Association of Clinical Endocrinologists, and named ‘Top 1% of U.S. Endocrinologists’ by US News and World Report.

Dr. Jeremy Pettus was diagnosed with type 1 diabetes when he was 15 years old. Since that time he has dedicated his career to educating and treating others like himself. He is currently an Endocrinologist and Assistant Professor of Medicine at the University of California, San Diego. There, he focuses primarily on clinical trials to develop and test new and innovative therapies for people living with diabetes. These include studies ranging from medications to reverse or slow the disease once it occurs, to islet cell transplantation strategies, to device studies such as artificial pancreas technology. As somebody who has the disease himself, sees patients with type 1, and is actively working on curing/treating the disease, we are honored to have him at TCOYD.
Successful Completion
To receive a Statement of Credit you must view the entire 60 min enduring activity. Your Statement of Credit will be issued electronically immediately upon submission of the evaluation form to the email address provided. Contact Olivia Montanari at olivia@tcoyd.org with questions.
Program Fees and Registration
This is a complimentary program. Registration is not required to view the materials, however, to obtain credit learners will be required to submit necessary identifying information, complete a post-test, and evaluation.
Acknowledgement of Joint Providership
This activity is jointly provided by The Association of Diabetes Care & Education Specialists (ADCES) and TCOYD. The Association of Diabetes Care & Education Specialists is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. ADCES’ Joint Accreditation Status also includes the Commission on Dietetic Registration (CDR) and American Academy of Physician Assistants (AAPA). ADCES will provide accreditation for this activity to ensure the content is scientifically based, accurate, current, and objective. Any conflicts among faculty or others involved in the planning and execution of this activity will be resolved.
This activity is provided as enduring material via tcoyd.org and will be available from 8/1/25 to 8/1/26.
– Acknowledgement of Financial Support –
This activity is supported by an educational grant from Abbott Diabetes Care
ACCREDITATION INFORMATION
This program is jointly provided with the Association of Diabetes Care & Education Specialists.
In support of improving patient care, this activity has been planned by Taking Control Of Your Diabetes and the Association of Diabetes Care & Education Specialists. Association of Diabetes Care & Education Specialists is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Accreditation Council for Pharmacy Education
The Universal Activity Number is JA4008258-9999-24-029-H01-P; JA4008258-9999-24-029-H01-T. This Knowledge-based activity has been approved for 1.0 contact hour(s). This statement contains information provided to NABP from the Accreditation Council for Pharmacy Education (ACPE) via CPE Monitor®. ACPE policy states paper and/or electronic statements of credit may no longer be distributed directly to learners as proof of ACPE credit. The official record of credit may be located in the learner’s e-profile in CPE Monitor.
American Medical Association (AMA)
Association of Diabetes Care & Education Specialists designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
Association of Diabetes Care & Education Specialists designates this activity for a maximum of 1.0 ANCC contact hours.
The Association of Diabetes Care & Education Specialists is approved by the California Board of Registered Nursing, Provider Number 10977, for 1.0 contact hours. RNs must retain this document for 4 years after the activity concludes.
The Association of Diabetes Care & Education Specialists has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Commission on Dietetic Registration (CDR): CDR Credentialed Practitioners will receive 1.0 Continuing Professional Education units (CPEUs) for completion of this activity. Completion of this RD/DTR profession-specific or IPCE activity awards CPEUs (One IPCE credit = One CPEU). If the activity is dietetics-related but not targeted to RDs or DTRs, CPEUs may be claimed which are commensurate with participation in contact hours (One 60 minute hour = 1 CPEU. RDs and DTRs are to select activity type 102 in their Activity Log. Sphere and Competency selection is at the learner’s discretion.
Certified Diabetes Care and Education Specialists: To satisfy the requirements for renewal of certification for the Certification Board for Diabetes Care and Education (CBDCE), continuing education activities must be diabetes related and approved by a provider on the CBDCE list of Approved Providers (www.cbdce.org). CBDCE does not approve continuing education. The Association of Diabetes Care & Education Specialists is on the CBDCE list of Approved Providers.
Other Health Professionals
It is the responsibility of each participant to determine if the program meets the criteria for re-licensure or recertification for their discipline.
Speaker Disclosures
In accordance with the ACCME Standards for Integrity and Independence, the Association of Diabetes Care & Education Specialists (ADCES) requires anyone in a position to affect or control continuing education content (e.g., authors, presenters, and program planners) to disclose all financial relationships with ineligible companies. It is the responsibility of ADCES to mitigate and disclose all relevant conflicts of interest. Disclosure of a relationship is not intended to suggest or condone bias in any presentation but is made to provide participants with information that might be of potential importance to their evaluation of the presentation.
Relevant disclosures (or lack thereof) among education activity planners and faculty are as follows:
Speakers:
Steven V. Edelman, MD
Board of Directors: Senseonics, Team Type 1 501(c)(3), TCOYD 501(c)(3)
Advisor/Consultant/Speaker: Eli Lilly, NovoNordisk, Vertex Pharmaceuticals, Sanofi, Xeris Pharmaceuticals
Shareholder: Senseonics
Jeremy H. Pettus, MD
Consultant: Carmot Therapeutics, NovoNordisk, Sanofi
Speakers Bureau: MannKind Corporation, Sanofi
All relevant relationships have been mitigated.
Planners:
Olivia Montanari – No Financial Relationships to Report
Autumn Zarlengo – No Financial Relationships to Report
Leave a Reply